CN114573839B - A preparation method of human hair keratin/chitosan hydrogel loaded with curcumin - Google Patents
A preparation method of human hair keratin/chitosan hydrogel loaded with curcumin Download PDFInfo
- Publication number
- CN114573839B CN114573839B CN202210340766.9A CN202210340766A CN114573839B CN 114573839 B CN114573839 B CN 114573839B CN 202210340766 A CN202210340766 A CN 202210340766A CN 114573839 B CN114573839 B CN 114573839B
- Authority
- CN
- China
- Prior art keywords
- human hair
- solution
- hair keratin
- chitosan
- hydrogel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title claims abstract description 172
- 108010076876 Keratins Proteins 0.000 title claims abstract description 136
- 102000011782 Keratins Human genes 0.000 title claims abstract description 136
- 239000000017 hydrogel Substances 0.000 title claims abstract description 100
- 235000012754 curcumin Nutrition 0.000 title claims abstract description 86
- 229940109262 curcumin Drugs 0.000 title claims abstract description 86
- 239000004148 curcumin Substances 0.000 title claims abstract description 86
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 title claims abstract description 86
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000000725 suspension Substances 0.000 claims abstract description 30
- 238000000605 extraction Methods 0.000 claims abstract description 29
- 239000002131 composite material Substances 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 238000004132 cross linking Methods 0.000 claims abstract description 15
- 238000005238 degreasing Methods 0.000 claims abstract description 13
- 235000019832 sodium triphosphate Nutrition 0.000 claims abstract description 12
- 238000004108 freeze drying Methods 0.000 claims abstract description 10
- 239000012141 concentrate Substances 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 124
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 238000000502 dialysis Methods 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 239000012153 distilled water Substances 0.000 claims description 15
- 239000012535 impurity Substances 0.000 claims description 15
- 239000011259 mixed solution Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 239000003431 cross linking reagent Substances 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 229910052979 sodium sulfide Inorganic materials 0.000 claims description 10
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 9
- 239000011521 glass Substances 0.000 claims description 5
- 230000003699 hair surface Effects 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 239000000344 soap Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000004506 ultrasonic cleaning Methods 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 abstract description 38
- 238000011084 recovery Methods 0.000 abstract description 10
- 230000008439 repair process Effects 0.000 abstract description 8
- 208000025962 Crush injury Diseases 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000005266 casting Methods 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 49
- 210000002027 skeletal muscle Anatomy 0.000 description 16
- 210000003050 axon Anatomy 0.000 description 15
- 208000014674 injury Diseases 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- 208000028389 Nerve injury Diseases 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 230000008764 nerve damage Effects 0.000 description 11
- 210000003497 sciatic nerve Anatomy 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 210000002683 foot Anatomy 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 210000003007 myelin sheath Anatomy 0.000 description 7
- 230000007830 nerve conduction Effects 0.000 description 7
- 210000000944 nerve tissue Anatomy 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000010886 Peripheral nerve injury Diseases 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000037444 atrophy Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 210000001087 myotubule Anatomy 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 229950003937 tolonium Drugs 0.000 description 5
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000036982 action potential Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 206010073696 Wallerian degeneration Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003822 epoxy resin Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229920000647 polyepoxide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000007832 reinnervation Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 230000008734 wallerian degeneration Effects 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010070245 Foreign body Diseases 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 206010048654 Muscle fibrosis Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000003519 biomedical and dental material Substances 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000020280 flat white Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- -1 low bioavailability Chemical compound 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000003666 myelinated nerve fiber Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 210000000431 third toe Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- XOSXWYQMOYSSKB-LDKJGXKFSA-L water blue Chemical compound CC1=CC(/C(\C(C=C2)=CC=C2NC(C=C2)=CC=C2S([O-])(=O)=O)=C(\C=C2)/C=C/C\2=N\C(C=C2)=CC=C2S([O-])(=O)=O)=CC(S(O)(=O)=O)=C1N.[Na+].[Na+] XOSXWYQMOYSSKB-LDKJGXKFSA-L 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1748—Keratin; Cytokeratin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2389/00—Characterised by the use of proteins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/13—Phenols; Phenolates
- C08K5/132—Phenols containing keto groups, e.g. benzophenones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及一种负载姜黄素的人发角蛋白/壳聚糖水凝胶的制备方法,属于水凝胶技术领域,包括以下步骤:人发角蛋白提取:先进行人发预处理和脱脂,然后进行人发角蛋白粗提取,再进行人发角蛋白纯化,最后进行人发角蛋白液浓缩,得人发角蛋白溶液;复合水凝胶制备:将人发角蛋白溶液与壳聚糖共混得共混液,将姜黄素加入后得混悬液,对混悬液冷冻干燥;交联得复合水凝胶。本发明通过浇铸、冷冻干燥和三聚磷酸钠交联的工艺可以制备负载姜黄素的人发角蛋白/壳聚糖水凝胶,负载姜黄素的人发角蛋白/壳聚糖水凝胶可以促进大鼠神经挤压伤恢复,促进效果优于单纯的水凝胶,人发角蛋白、壳聚糖和姜黄素可以协同发挥对神经修复的促进作用。
The invention relates to a preparation method of curcumin-loaded human hair keratin/chitosan hydrogel, which belongs to the field of hydrogel technology, and comprises the following steps: human hair keratin extraction: human hair pretreatment and degreasing, and then Carry out crude extraction of human hair keratin, then purify human hair keratin, and finally concentrate human hair keratin solution to obtain human hair keratin solution; preparation of composite hydrogel: blend human hair keratin solution with chitosan The blend solution is obtained, the curcumin is added to obtain a suspension, and the suspension is freeze-dried; cross-linked to obtain a composite hydrogel. The present invention can prepare the curcumin-loaded human hair keratin/chitosan hydrogel by casting, freeze-drying and sodium tripolyphosphate cross-linking techniques, and the human hair keratin/chitosan hydrogel loaded curcumin can promote large The recovery of rat nerve crush injury is better than that of simple hydrogel, and human hair keratin, chitosan and curcumin can synergistically play a role in promoting nerve repair.
Description
技术领域technical field
本发明涉及水凝胶技术领域,具体是一种负载姜黄素的人发角蛋白/壳聚糖水凝胶的制备方法。The invention relates to the field of hydrogel technology, in particular to a preparation method of curcumin-loaded human hair keratin/chitosan hydrogel.
背景技术Background technique
周围神经损伤(peripheral nerve injury,PNI)是临床常见创伤,创伤原因包括切割、牵拉、压迫及其他特殊原因等。在四肢创伤患者中,约有2-3%的患者存在神经损伤,其中挤压伤占比较高,而这一部分神经损伤的患者年龄小于55岁约有83%,给社会带来巨大损失。虽然与中枢神经系统相比,外周神经系统在损伤后具有一定再生的能力,但其再生缓慢约1-3mm/天。这也代表远离靶器官的损伤会有较长的恢复过程,长时间失神经支配会使靶器官退化,包括肌肉萎缩和纤维化、感觉障碍、运动障碍,甚至是功能缺失而导致终身残疾,进而对患者心理健康和日常生活产生严重影响。Peripheral nerve injury (PNI) is a common clinical trauma, and the causes of trauma include cutting, stretching, compression and other special reasons. Among patients with limb trauma, about 2-3% of patients have nerve damage, among which crush injuries account for a relatively high proportion, and about 83% of patients with nerve damage under the age of 55 have brought huge losses to society. Although the peripheral nervous system has some ability to regenerate after injury compared with the central nervous system, its regeneration is about 1-3mm/day slower. This also means that injuries far away from the target organ will have a longer recovery process, and long-term denervation will cause target organ degeneration, including muscle atrophy and fibrosis, sensory impairment, motor impairment, and even loss of function leading to permanent disability, and then It has a serious impact on the patient's mental health and daily life.
及时有针对的治疗手段会使周围神经损伤预后发生改善。当损伤涉及轴突时,神经会经历三个主要过程:华勒氏变性(远端残端的清除过程)、轴突再生和靶器官神经再支配。在发生神经离断和神经缺损时,神经吻合与自体神经移植仍是主要治疗手段;而当发生严重挤压以及慢性压迫时神经松解手术是有益的治疗方法。尽管治疗方法有效,但神经恢复周期仍然较长,患者恢复效果不尽满意。除常规手术治疗外,更丰富的治疗办法仍然需要研究。Timely and targeted treatment will improve the prognosis of peripheral nerve injury. When injury involves axons, the nerve undergoes three major processes: Wallerian degeneration (clearing of the distal stump), axonal regeneration, and target organ reinnervation. Nerve anastomosis and autologous nerve transplantation are still the main treatment methods when nerve transection and nerve defect occur; while nerve release surgery is a beneficial treatment method when severe compression and chronic compression occur. Although the treatment method is effective, the nerve recovery period is still long, and the recovery effect of patients is not satisfactory. In addition to conventional surgical treatment, more abundant treatment options still need to be studied.
药物治疗是可靠手段之一,众多药物已被开发,如地塞米松、他克莫司、维生素B12、白藜芦醇、姜黄素等,研究表明这些药物有促进神经损伤修复的能力。从姜黄根茎中取的姜黄素作为PNI治疗药物已被广泛研究,主要作用机制包括促进SCs的增殖和迁移,减少SCs的凋亡,保护被根神经节,抑制氧化应激和抵抗炎症等。这些研究结果揭示了姜黄素在PNI的应用前景。但姜黄素的生物利用度低、吸收不良、代谢率高等特点使其难以针对性的在损伤神经周围持久的发挥作用。Drug treatment is one of the reliable means, and many drugs have been developed, such as dexamethasone, tacrolimus, vitamin B12, resveratrol, curcumin, etc. Studies have shown that these drugs have the ability to promote the repair of nerve damage. Curcumin from turmeric rhizomes has been widely studied as a drug for PNI treatment. The main mechanism of action includes promoting the proliferation and migration of SCs, reducing the apoptosis of SCs, protecting the root ganglion, inhibiting oxidative stress and resisting inflammation. These findings reveal the application prospect of curcumin in PNI. However, the characteristics of curcumin such as low bioavailability, malabsorption, and high metabolic rate make it difficult to exert a targeted and lasting effect on the damaged nerves.
水凝胶是组织工程领域中生物医学材料的常见形式,其固有的物理化学和生物学特性,包括高含水量、与天然ECM相似的结构、多孔结构、可调节的生物降解性和生物相容性,这些优异的特征支持其作为载体来提供局部药物输送。生物材料基本要求包括生物相容性、生物降解性和适当的机械性能。常用的材料包括天然聚合物(角蛋白、胶原蛋白、明胶、纤维素、壳聚糖聚等)和合成聚合物(聚乳酸、聚乙醇酸、聚己内酯等)。人发角蛋白是从人头发中提取的天然聚合物,与合成类聚合物相比具备出色的生物相容性和生物降解性,并且已有研究证实其具备促进神经再生的能力。但角蛋白本身的脆弱性、低强度和低柔韧性限制了角蛋白在生物医学领域中的应用。聚合物的共混可以开发具有增强特性/功能/活性的材料,新材料可以保留部分原材料的优点,并且能通过改变原材料比例来合成更具优势的新聚合物。壳聚糖同样是应用较为广泛的生物医学材料,相比于角蛋白其具备更强的机械性能,故壳聚糖与角蛋白共混有望改善角蛋白的力学性能上的缺点。Hydrogels are a common form of biomedical materials in the field of tissue engineering due to their inherent physicochemical and biological properties, including high water content, structure similar to natural ECM, porous structure, tunable biodegradability, and biocompatibility These excellent features support their use as carriers to provide localized drug delivery. Basic requirements for biomaterials include biocompatibility, biodegradability, and appropriate mechanical properties. Commonly used materials include natural polymers (keratin, collagen, gelatin, cellulose, chitosan, etc.) and synthetic polymers (polylactic acid, polyglycolic acid, polycaprolactone, etc.). Human hair keratin is a natural polymer extracted from human hair. Compared with synthetic polymers, human hair keratin has excellent biocompatibility and biodegradability, and studies have confirmed its ability to promote nerve regeneration. However, the fragility, low strength and low flexibility of keratin itself limit the application of keratin in the field of biomedicine. The blending of polymers can develop materials with enhanced properties/functions/activity, new materials can retain some of the advantages of raw materials, and new polymers with more advantages can be synthesized by changing the ratio of raw materials. Chitosan is also a widely used biomedical material. Compared with keratin, it has stronger mechanical properties. Therefore, the blending of chitosan and keratin is expected to improve the shortcomings of keratin's mechanical properties.
发明内容Contents of the invention
本发明的目的在于提供一种负载姜黄素的人发角蛋白/壳聚糖水凝胶的制备方法,以解决上述背景技术中提出的问题。The object of the present invention is to provide a kind of preparation method of the human hair keratin/chitosan hydrogel of loading curcumin, to solve the problem proposed in the above-mentioned background technology.
为实现上述目的,本发明提供如下技术方案:To achieve the above object, the present invention provides the following technical solutions:
一种负载姜黄素的人发角蛋白/壳聚糖水凝胶的制备方法,包括以下步骤:A preparation method of human hair keratin/chitosan hydrogel loaded with curcumin, comprising the following steps:
人发角蛋白提取:先进行人发预处理和脱脂,然后进行人发角蛋白粗提取,再进行人发角蛋白纯化,最后进行人发角蛋白液浓缩,得人发角蛋白溶液;Extraction of human hair keratin: first pretreatment and degreasing of human hair, then rough extraction of human hair keratin, purification of human hair keratin, and concentration of human hair keratin solution to obtain human hair keratin solution;
复合水凝胶制备:将人发角蛋白溶液与壳聚糖共混得共混液,将姜黄素加入后得混悬液,对混悬液冷冻干燥;交联得复合水凝胶。Preparation of the composite hydrogel: blending human hair keratin solution and chitosan to obtain a blend, adding curcumin to obtain a suspension, and freeze-drying the suspension; cross-linking to obtain a composite hydrogel.
作为本发明的进一步技术方案,所述人发预处理和脱脂为:将人发剪为1-2cm小段,然后用肥皂和清水洗去头发表面的杂质,然后用体积比为2:1的氯仿和甲醇混合溶液对人发进行浸泡脱脂24小时,期间每隔8小时用玻璃棒搅拌溶液以保证人发和混合液的充分接触,脱脂后用乙醇清洗头发3-4次将残留的混合溶液洗净,然后将人发晾干备用。As a further technical solution of the present invention, the human hair pretreatment and degreasing are as follows: human hair is cut into 1-2cm segments, then the impurities on the hair surface are washed away with soap and water, and then chloroform with a volume ratio of 2:1 Soak and degrease human hair with a mixed solution of methanol for 24 hours. During this period, stir the solution with a glass rod every 8 hours to ensure full contact between human hair and the mixed solution. After degreasing, wash the hair with ethanol for 3-4 times to wash off the residual mixed solution. , and then dry the human hair for later use.
作为本发明的更进一步技术方案,所述人发角蛋白粗提取为:称取20g干燥人发置于500ml的三口圆底烧瓶中,再加入蒸馏水配制的0.125M硫化钠溶液至500ml,混匀后将烧瓶固定于恒温水浴锅中,在40℃下反应5小时,反应过程中用搅拌器适度搅拌,反应结束后用200目筛网过滤反应液以去除额外的人发纤维,之后再将溶液离心进一步去除溶液中的杂质,所得上清液即为人发角蛋白粗提取溶液。As a further technical solution of the present invention, the crude extraction of human hair keratin is as follows: Weigh 20g of dry human hair and place it in a 500ml three-neck round bottom flask, then add 0.125M sodium sulfide solution prepared with distilled water to 500ml, and mix well Finally, fix the flask in a constant temperature water bath and react at 40°C for 5 hours. During the reaction, use a stirrer to stir moderately. After the reaction, filter the reaction solution with a 200-mesh screen to remove extra human hair fibers, and then dissolve the solution The impurities in the solution are further removed by centrifugation, and the obtained supernatant is the crude human hair keratin extraction solution.
作为本发明的再进一步技术方案,所述人发角蛋白纯化为:将人发角蛋白粗提取溶液用10kDa透析袋进行透析,以去除反应液中的硫化钠等杂质,透析液缓冲液为蒸馏水,透析时间为72小时,最初24小时每隔8小时换水一次,之后则每隔12小时换水一次,透析袋中粗提取溶液的初始容积需小于透析袋的体积1/4,以防止透析过程中溶液体积过大撑破透析袋。As a further technical solution of the present invention, the human hair keratin is purified as follows: the human hair keratin crude extraction solution is dialyzed with a 10kDa dialysis bag to remove impurities such as sodium sulfide in the reaction solution, and the dialysate buffer is distilled water , the dialysis time is 72 hours, the water is changed every 8 hours in the first 24 hours, and then every 12 hours after that, the initial volume of the crude extraction solution in the dialysis bag should be less than 1/4 of the volume of the dialysis bag to prevent dialysis During the process, the volume of the solution is too large to burst the dialysis bag.
作为本发明的再进一步技术方案,所述人发角蛋白液浓缩为:将透析后的人发角蛋白溶液倒入圆底烧瓶中,用旋转蒸发仪对溶液进行浓缩,缓慢升温至加热温度为55℃,转速在5-20rpm,初步浓缩后的人发角蛋白溶液再次离心去除真空浓缩过程中产生的絮状物,最终得到纯净的人发角蛋白溶液,用Bradford蛋白浓度测定蛋白浓度,并储存于4℃冰箱中备用。As a further technical solution of the present invention, the human hair keratin solution is concentrated as follows: pour the dialyzed human hair keratin solution into a round bottom flask, concentrate the solution with a rotary evaporator, and slowly heat up to a heating temperature of 55°C, with a rotation speed of 5-20rpm, the human hair keratin solution after the initial concentration was centrifuged again to remove the flocs produced in the vacuum concentration process, and finally a pure human hair keratin solution was obtained, and the protein concentration was determined by Bradford protein concentration, and Store in a 4°C refrigerator for later use.
作为本发明的再进一步技术方案,所述人发角蛋白溶液与壳聚糖共混为:称取壳聚糖粉末置于50ml离心管中,对人发角蛋白溶液进行稀释,把稀释后的角蛋白溶液加入到离心管中,轻微摇晃使壳聚糖粉末与人发角蛋白溶液充分混合,并迅速用移液器向试管中加入人发角蛋白/壳聚糖共混液1%体积的乙酸使壳聚糖粉末质子化溶解,剧烈摇晃试管后得到人发角蛋白/壳聚糖混悬液,使壳聚糖和人发角蛋白总质量浓度为20mg/ml,然后将姜黄素加入试管并摇晃均匀,将试管置于超声清洗仪中超声20min去除摇晃过程中产生的气泡,之后用注射器吸取混悬液加入到不同形状的模具中。As a further technical solution of the present invention, the human hair keratin solution is blended with chitosan as follows: take chitosan powder and place it in a 50ml centrifuge tube, dilute the human hair keratin solution, and dilute the diluted Add the keratin solution into the centrifuge tube, shake slightly to mix the chitosan powder and the human hair keratin solution, and quickly add 1% acetic acid of the human hair keratin/chitosan blend to the test tube with a pipette The chitosan powder is protonated and dissolved, and the human hair keratin/chitosan suspension is obtained after vigorously shaking the test tube, so that the total mass concentration of chitosan and human hair keratin is 20mg/ml, then curcumin is added to the test tube and Shake evenly, place the test tube in an ultrasonic cleaner for 20 minutes to remove air bubbles generated during the shaking process, and then use a syringe to draw the suspension and add it to molds of different shapes.
作为本发明的再进一步技术方案,所述壳聚糖与人发角蛋白的质量比为1:1。As a further technical solution of the present invention, the mass ratio of chitosan to human hair keratin is 1:1.
作为本发明的再进一步技术方案,所述姜黄素质量浓度为6mg/ml。As a further technical solution of the present invention, the curcumin mass concentration is 6 mg/ml.
作为本发明的再进一步技术方案,所述混悬液冷冻干燥为:把模具放于冰箱中,在-20℃下将混悬液迅速冷冻,冷冻后将模具转移至冷冻干燥机中冻干过夜。As a further technical solution of the present invention, the freeze-drying of the suspension is as follows: put the mold in the refrigerator, freeze the suspension rapidly at -20°C, and transfer the mold to a freeze dryer to freeze-dry overnight .
作为本发明的再进一步技术方案,所述交联为:配制3%三聚磷酸钠和pH=5的1.5M氯化钠溶液作为交联剂,加入交联剂浸没冻干的水凝胶静置交联20min,之后用蒸馏水反复清洗水凝胶去除多余的三聚磷酸钠和氯化钠,得到最终的复合水凝胶。As a further technical solution of the present invention, the cross-linking is: preparing 3% sodium tripolyphosphate and 1.5M sodium chloride solution with pH=5 as a cross-linking agent, adding the cross-linking agent to immerse the lyophilized hydrogel statically After cross-linking for 20 minutes, the hydrogel was repeatedly washed with distilled water to remove excess sodium tripolyphosphate and sodium chloride to obtain the final composite hydrogel.
与现有技术相比,本发明的有益效果是:通过浇铸、冷冻干燥和三聚磷酸钠交联的工艺可以制备负载姜黄素的人发角蛋白/壳聚糖水凝胶,负载姜黄素的人发角蛋白/壳聚糖水凝胶可以促进大鼠神经挤压伤恢复,其中负载姜黄素的水凝胶促进效果优于单纯的水凝胶,人发角蛋白、壳聚糖和姜黄素可以协同发挥对神经修复的促进作用。Compared with the prior art, the beneficial effects of the present invention are: the curcumin-loaded human hair keratin/chitosan hydrogel can be prepared by casting, freeze-drying and sodium tripolyphosphate cross-linking techniques, and the curcumin-loaded human hair keratin/chitosan hydrogel Hair keratin/chitosan hydrogel can promote the recovery of nerve crush injury in rats, and the hydrogel loaded with curcumin has a better promoting effect than pure hydrogel. Human hair keratin, chitosan and curcumin can synergistically Play a role in promoting nerve repair.
附图说明Description of drawings
图1为不同浓度姜黄素的RSC细胞划痕实验图;Fig. 1 is the RSC cell scratch experiment diagram of different concentrations of curcumin;
图2的A为人发角蛋白/壳聚糖水凝胶和负载姜黄素的人发角蛋白/壳聚糖水凝胶的结构示意图;A of Fig. 2 is the structural representation of human hair keratin/chitosan hydrogel and the human hair keratin/chitosan hydrogel of loading curcumin;
图2的B为姜黄素浓度-吸光度的标准曲线图;B of Fig. 2 is the standard curve figure of curcumin concentration-absorbance;
图2的C为姜黄素释放率图;C of Fig. 2 is the figure of curcumin release rate;
图3的A为水凝胶植入大鼠神经周围8周降解情况图;A of Fig. 3 is a diagram of the degradation of the hydrogel implanted around the rat nerve for 8 weeks;
图3的B为水凝胶植入第4周大鼠重要脏器HE染色图;Figure 3 B is the HE staining image of the important organs of rats at the 4th week of hydrogel implantation;
图3的C为水凝胶植入后4周内大鼠体重变化图;Figure 3 C is a graph of the body weight change of rats within 4 weeks after hydrogel implantation;
图3的D为水凝胶植入后4周内大鼠血液中TNT-α表达水平图;D of Fig. 3 is the expression level map of TNT-α in rat blood within 4 weeks after hydrogel implantation;
图3的E为水凝胶植入后4周内大鼠血液中IL-10表达水平图;E of Fig. 3 is the expression level figure of IL-10 in rat blood within 4 weeks after hydrogel implantation;
图4的A为4周内大鼠足印变化图;A of Fig. 4 is the change figure of rat's footprint in 4 weeks;
图4的B为SFI测量及计算示意图;B of Figure 4 is a schematic diagram of SFI measurement and calculation;
图4的C为SFI统计分析图;C of Fig. 4 is the SFI statistical analysis diagram;
图5的A为图不同实验组复合肌肉动作电位记录图;A of Fig. 5 is a recording diagram of compound muscle action potentials in different experimental groups;
图5的B为再生神经的传导速度图;B of Figure 5 is the conduction velocity diagram of the regenerated nerve;
图5的C为再生神经的CMPA峰值振幅图(*,P<0.05;**,P<0.01);Figure 5 C is the CMPA peak amplitude map of regenerated nerves (*, P<0.05; **, P<0.01);
图6的A为甲苯胺兰染色图(1000×观察);A of Fig. 6 is a toluidine blue staining figure (1000 × observation);
图6的B为透射电镜图;B of Fig. 6 is transmission electron micrograph;
图6的C为轴突计数图;C of Fig. 6 is axon count map;
图6的D为轴突内直径图;D in Figure 6 is a diagram of the inner diameter of the axon;
图6的E为轴突内直径/总限位直径(G-比值)图;E of Fig. 6 is axon inner diameter/total stop diameter (G-ratio) figure;
图6的F为髓鞘厚度图(*,P<0.05;**,P<0.01);F in Fig. 6 is the map of myelin sheath thickness (*, P<0.05; **, P<0.01);
图7的A为腓肠肌的外观图;A of Fig. 7 is the exterior view of the gastrocnemius muscle;
图7的B为腓肠肌横截面的Masson染色图;B of Fig. 7 is the Masson staining picture of gastrocnemius muscle cross section;
图7的C为腓肠肌相对湿重图;C of Fig. 7 is the gastrocnemius relative wet weight map;
图7的D为腓肠肌横截面肌纤维面积占比图(*,P<0.05;**,P<0.01)。D in Figure 7 is a map of the proportion of muscle fiber area in the gastrocnemius muscle cross section (*, P<0.05; **, P<0.01).
具体实施方式Detailed ways
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述。The following will clearly and completely describe the technical solutions in the embodiments of the present invention with reference to the drawings in the embodiments of the present invention.
实施例1Example 1
一种负载姜黄素的人发角蛋白/壳聚糖水凝胶的制备方法,包括以下步骤:A preparation method of human hair keratin/chitosan hydrogel loaded with curcumin, comprising the following steps:
S1、人发角蛋白提取:S1. Human hair keratin extraction:
1、人发预处理和脱脂:将人发剪为1-2cm小段,然后用肥皂和清水洗去头发表面的杂质,然后用体积比为2:1的氯仿和甲醇混合溶液对人发进行浸泡脱脂24小时,期间每隔8小时用玻璃棒搅拌溶液以保证人发和混合液的充分接触,脱脂后用乙醇清洗头发3-4次将残留的混合溶液洗净,然后将人发晾干备用;1. Human hair pretreatment and degreasing: cut human hair into 1-2cm sections, then wash off the impurities on the hair surface with soap and water, and then soak human hair in a mixed solution of chloroform and methanol with a volume ratio of 2:1 Degrease for 24 hours. During this period, use a glass rod to stir the solution every 8 hours to ensure full contact between the human hair and the mixed solution. After degreasing, wash the hair with ethanol for 3-4 times to wash off the residual mixed solution, and then dry the human hair for later use;
2、人发角蛋白粗提取:称取20g干燥人发置于500ml的三口圆底烧瓶中,再加入蒸馏水配制的0.125M硫化钠溶液至500ml,混匀后将烧瓶固定于恒温水浴锅中,在40℃下反应5小时,反应过程中用搅拌器适度搅拌,反应结束后用200目筛网过滤反应液以去除额外的人发纤维,之后再将溶液离心进一步去除溶液中的杂质,所得上清液即为人发角蛋白粗提取溶液;2. Crude extraction of human hair keratin: Weigh 20g of dry human hair and place it in a 500ml three-necked round bottom flask, then add 0.125M sodium sulfide solution prepared with distilled water to 500ml, mix well and fix the flask in a constant temperature water bath. React at 40°C for 5 hours, moderately stir with a stirrer during the reaction, filter the reaction solution with a 200-mesh screen to remove extra human hair fibers after the reaction, and then centrifuge the solution to further remove impurities in the solution, the above obtained The serum is the human hair keratin crude extraction solution;
3、人发角蛋白纯化:将人发角蛋白粗提取溶液用10kDa透析袋进行透析,以去除反应液中的硫化钠等杂质,透析液缓冲液为蒸馏水,透析时间为72小时,最初24小时每隔8小时换水一次,之后则每隔12小时换水一次,透析袋中粗提取溶液的初始容积需小于透析袋的体积1/4,以防止透析过程中溶液体积过大撑破透析袋;3. Purification of human hair keratin: Dialyze the crude human hair keratin extraction solution with a 10kDa dialysis bag to remove impurities such as sodium sulfide in the reaction solution. The dialysate buffer is distilled water, and the dialysis time is 72 hours, the first 24 hours Change the water every 8 hours, and then change the water every 12 hours. The initial volume of the crude extraction solution in the dialysis bag should be less than 1/4 of the volume of the dialysis bag to prevent the solution from breaking the dialysis bag during dialysis. ;
4、人发角蛋白液浓缩,将透析后的人发角蛋白溶液倒入圆底烧瓶中,用旋转蒸发仪对溶液进行浓缩,缓慢升温至加热温度为55℃,转速在5-20rpm,初步浓缩后的人发角蛋白溶液再次离心去除真空浓缩过程中产生的絮状物,最终得到纯净的人发角蛋白溶液,用Bradford蛋白浓度测定蛋白浓度,并储存于4℃冰箱中备用;4. Concentrate the human hair keratin solution. Pour the dialyzed human hair keratin solution into a round bottom flask, concentrate the solution with a rotary evaporator, and slowly heat up to a heating temperature of 55°C with a rotation speed of 5-20rpm. The concentrated human hair keratin solution was centrifuged again to remove the flocs produced in the vacuum concentration process, and finally a pure human hair keratin solution was obtained. The protein concentration was determined by Bradford protein concentration, and stored in a refrigerator at 4°C for use;
S2、复合水凝胶制备S2. Preparation of composite hydrogel
1、混悬液制备:称取0.12g壳聚糖粉末置于50ml离心管中,对人发角蛋白溶液进行稀释,把4ml稀释后的角蛋白溶液(20mg/ml)加入到离心管中,轻微摇晃使壳聚糖粉末与人发角蛋白溶液充分混合,并迅速用移液器向试管中加入人发角蛋白/壳聚糖共混液1%体积的乙酸使壳聚糖粉末质子化溶解,剧烈摇晃试管后得到人发角蛋白/壳聚糖混悬液,然后将姜黄素加入试管并摇晃均匀(1ml共混液中加入6mg姜黄素),将试管置于超声清洗仪中超声20min去除摇晃过程中产生的气泡,之后用注射器吸取混悬液加入到不同形状的模具中;1. Suspension preparation: Weigh 0.12g chitosan powder and place it in a 50ml centrifuge tube, dilute the human hair keratin solution, add 4ml diluted keratin solution (20mg/ml) into the centrifuge tube, Shake slightly to make the chitosan powder and human hair keratin solution fully mixed, and quickly add 1% acetic acid of human hair keratin/chitosan blend solution to the test tube with a pipette to protonate and dissolve the chitosan powder, Vigorously shake the test tube to obtain a human hair keratin/chitosan suspension, then add curcumin to the test tube and shake evenly (6mg curcumin is added to 1ml blend), put the test tube in an ultrasonic cleaner for 20min to remove the shaking process The bubbles generated in the medium, and then use the syringe to draw the suspension and add it to different shapes of molds;
2、混悬液冷冻干燥:把模具放于冰箱中,在-20℃下将混悬液迅速冷冻,冷冻后将模具转移至冷冻干燥机中冻干过夜;2. Freeze-drying of the suspension: put the mold in the refrigerator, freeze the suspension quickly at -20°C, and transfer the mold to a freeze dryer to freeze-dry overnight;
3、交联:配制3%三聚磷酸钠和pH=5的1.5M氯化钠溶液作为交联剂,加入交联剂浸没冻干的水凝胶静置交联20min,之后用蒸馏水反复清洗水凝胶去除多余的三聚磷酸钠和氯化钠,得到最终的复合水凝胶。3. Cross-linking: prepare 3% sodium tripolyphosphate and 1.5M sodium chloride solution with pH=5 as a cross-linking agent, add the cross-linking agent to immerse the freeze-dried hydrogel and let stand for cross-linking for 20 minutes, then wash it repeatedly with distilled water The hydrogel removes excess sodium tripolyphosphate and sodium chloride to obtain the final composite hydrogel.
实施例2Example 2
一种负载姜黄素的人发角蛋白/壳聚糖水凝胶的制备方法,包括以下步骤:A preparation method of human hair keratin/chitosan hydrogel loaded with curcumin, comprising the following steps:
S1、人发角蛋白提取:S1. Human hair keratin extraction:
1、人发预处理和脱脂:将人发剪为1-2cm小段,然后用肥皂和清水洗去头发表面的杂质,然后用体积比为2:1的氯仿和甲醇混合溶液对人发进行浸泡脱脂24小时,期间每隔8小时用玻璃棒搅拌溶液以保证人发和混合液的充分接触,脱脂后用乙醇清洗头发3-4次将残留的混合溶液洗净,然后将人发晾干备用;1. Human hair pretreatment and degreasing: cut human hair into 1-2cm sections, then wash off the impurities on the hair surface with soap and water, and then soak human hair in a mixed solution of chloroform and methanol with a volume ratio of 2:1 Degrease for 24 hours. During this period, use a glass rod to stir the solution every 8 hours to ensure full contact between the human hair and the mixed solution. After degreasing, wash the hair with ethanol for 3-4 times to wash off the residual mixed solution, and then dry the human hair for later use;
2、人发角蛋白粗提取:称取20g干燥人发置于500ml的三口圆底烧瓶中,再加入蒸馏水配制的0.125M硫化钠溶液至500ml,混匀后将烧瓶固定于恒温水浴锅中,在40℃下反应5小时,反应过程中用搅拌器适度搅拌,反应结束后用200目筛网过滤反应液以去除额外的人发纤维,之后再将溶液离心进一步去除溶液中的杂质,所得上清液即为人发角蛋白粗提取溶液;2. Crude extraction of human hair keratin: Weigh 20g of dry human hair and place it in a 500ml three-necked round bottom flask, then add 0.125M sodium sulfide solution prepared with distilled water to 500ml, mix well and fix the flask in a constant temperature water bath. React at 40°C for 5 hours, moderately stir with a stirrer during the reaction, filter the reaction solution with a 200-mesh screen to remove extra human hair fibers after the reaction, and then centrifuge the solution to further remove impurities in the solution, the above obtained The serum is the human hair keratin crude extraction solution;
3、人发角蛋白纯化:将人发角蛋白粗提取溶液用10kDa透析袋进行透析,以去除反应液中的硫化钠等杂质,透析液缓冲液为蒸馏水,透析时间为72小时,最初24小时每隔8小时换水一次,之后则每隔12小时换水一次,透析袋中粗提取溶液的初始容积需小于透析袋的体积1/4,以防止透析过程中溶液体积过大撑破透析袋;3. Purification of human hair keratin: Dialyze the crude human hair keratin extraction solution with a 10kDa dialysis bag to remove impurities such as sodium sulfide in the reaction solution. The dialysate buffer is distilled water, and the dialysis time is 72 hours, the first 24 hours Change the water every 8 hours, and then change the water every 12 hours. The initial volume of the crude extraction solution in the dialysis bag should be less than 1/4 of the volume of the dialysis bag to prevent the solution from breaking the dialysis bag during dialysis. ;
4、人发角蛋白液浓缩,将透析后的人发角蛋白溶液倒入圆底烧瓶中,用旋转蒸发仪对溶液进行浓缩,缓慢升温至加热温度为55℃,转速在5-20rpm,初步浓缩后的人发角蛋白溶液再次离心去除真空浓缩过程中产生的絮状物,最终得到纯净的人发角蛋白溶液,用Bradford蛋白浓度测定蛋白浓度,并储存于4℃冰箱中备用;4. Concentrate the human hair keratin solution. Pour the dialyzed human hair keratin solution into a round bottom flask, concentrate the solution with a rotary evaporator, and slowly heat up to a heating temperature of 55°C with a rotation speed of 5-20rpm. The concentrated human hair keratin solution was centrifuged again to remove the flocs produced in the vacuum concentration process, and finally a pure human hair keratin solution was obtained. The protein concentration was determined by Bradford protein concentration, and stored in a refrigerator at 4°C for use;
S2、复合水凝胶制备S2. Preparation of composite hydrogel
1、混悬液制备:称取0.10g壳聚糖粉末置于50ml离心管中,对人发角蛋白溶液进行稀释,把5ml稀释后的角蛋白溶液(20mg/ml)加入到离心管中,轻微摇晃使壳聚糖粉末与人发角蛋白溶液充分混合,并迅速用移液器向试管中加入人发角蛋白/壳聚糖共混液1%体积的乙酸使壳聚糖粉末质子化溶解,剧烈摇晃试管后得到人发角蛋白/壳聚糖混悬液,然后将姜黄素加入试管并摇晃均匀(1ml共混液中加入6mg姜黄素),将试管置于超声清洗仪中超声20min去除摇晃过程中产生的气泡,之后用注射器吸取混悬液加入到不同形状的模具中;1. Suspension preparation: Weigh 0.10g chitosan powder and place it in a 50ml centrifuge tube, dilute the human hair keratin solution, add 5ml diluted keratin solution (20mg/ml) into the centrifuge tube, Shake slightly to make the chitosan powder and human hair keratin solution fully mixed, and quickly add 1% acetic acid of human hair keratin/chitosan blend solution to the test tube with a pipette to protonate and dissolve the chitosan powder, Vigorously shake the test tube to obtain a human hair keratin/chitosan suspension, then add curcumin to the test tube and shake evenly (6mg curcumin is added to 1ml blend), put the test tube in an ultrasonic cleaner for 20min to remove the shaking process The bubbles generated in the medium, and then use the syringe to draw the suspension and add it to different shapes of molds;
2、混悬液冷冻干燥:把模具放于冰箱中,在-20℃下将混悬液迅速冷冻,冷冻后将模具转移至冷冻干燥机中冻干过夜;2. Freeze-drying of the suspension: put the mold in the refrigerator, freeze the suspension quickly at -20°C, and transfer the mold to a freeze dryer to freeze-dry overnight;
3、交联:配制3%三聚磷酸钠和pH=5的1.5M氯化钠溶液作为交联剂,加入交联剂浸没冻干的水凝胶静置交联20min,之后用蒸馏水反复清洗水凝胶去除多余的三聚磷酸钠和氯化钠,得到最终的复合水凝胶。3. Cross-linking: prepare 3% sodium tripolyphosphate and 1.5M sodium chloride solution with pH=5 as a cross-linking agent, add the cross-linking agent to immerse the freeze-dried hydrogel and let stand for cross-linking for 20 minutes, then wash it repeatedly with distilled water The hydrogel removes excess sodium tripolyphosphate and sodium chloride to obtain the final composite hydrogel.
实施例3Example 3
一种负载姜黄素的人发角蛋白/壳聚糖水凝胶的制备方法,包括以下步骤:A preparation method of human hair keratin/chitosan hydrogel loaded with curcumin, comprising the following steps:
S1、人发角蛋白提取:S1. Human hair keratin extraction:
1、人发预处理和脱脂:将人发剪为1-2cm小段,然后用肥皂和清水洗去头发表面的杂质,然后用体积比为2:1的氯仿和甲醇混合溶液对人发进行浸泡脱脂24小时,期间每隔8小时用玻璃棒搅拌溶液以保证人发和混合液的充分接触,脱脂后用乙醇清洗头发3-4次将残留的混合溶液洗净,然后将人发晾干备用;1. Human hair pretreatment and degreasing: cut human hair into 1-2cm sections, then wash off the impurities on the hair surface with soap and water, and then soak human hair in a mixed solution of chloroform and methanol with a volume ratio of 2:1 Degrease for 24 hours. During this period, use a glass rod to stir the solution every 8 hours to ensure full contact between the human hair and the mixed solution. After degreasing, wash the hair with ethanol for 3-4 times to wash off the residual mixed solution, and then dry the human hair for later use;
2、人发角蛋白粗提取:称取20g干燥人发置于500ml的三口圆底烧瓶中,再加入蒸馏水配制的0.125M硫化钠溶液至500ml,混匀后将烧瓶固定于恒温水浴锅中,在40℃下反应5小时,反应过程中用搅拌器适度搅拌,反应结束后用200目筛网过滤反应液以去除额外的人发纤维,之后再将溶液离心进一步去除溶液中的杂质,所得上清液即为人发角蛋白粗提取溶液;2. Crude extraction of human hair keratin: Weigh 20g of dry human hair and place it in a 500ml three-necked round bottom flask, then add 0.125M sodium sulfide solution prepared with distilled water to 500ml, mix well and fix the flask in a constant temperature water bath. React at 40°C for 5 hours, moderately stir with a stirrer during the reaction, filter the reaction solution with a 200-mesh screen to remove extra human hair fibers after the reaction, and then centrifuge the solution to further remove impurities in the solution, the above obtained The serum is the human hair keratin crude extraction solution;
3、人发角蛋白纯化:将人发角蛋白粗提取溶液用10kDa透析袋进行透析,以去除反应液中的硫化钠等杂质,透析液缓冲液为蒸馏水,透析时间为72小时,最初24小时每隔8小时换水一次,之后则每隔12小时换水一次,透析袋中粗提取溶液的初始容积需小于透析袋的体积1/4,以防止透析过程中溶液体积过大撑破透析袋;3. Purification of human hair keratin: Dialyze the crude human hair keratin extraction solution with a 10kDa dialysis bag to remove impurities such as sodium sulfide in the reaction solution. The dialysate buffer is distilled water, and the dialysis time is 72 hours, the first 24 hours Change the water every 8 hours, and then change the water every 12 hours. The initial volume of the crude extraction solution in the dialysis bag should be less than 1/4 of the volume of the dialysis bag to prevent the solution from breaking the dialysis bag during dialysis. ;
4、人发角蛋白液浓缩,将透析后的人发角蛋白溶液倒入圆底烧瓶中,用旋转蒸发仪对溶液进行浓缩,缓慢升温至加热温度为55℃,转速在5-20rpm,初步浓缩后的人发角蛋白溶液再次离心去除真空浓缩过程中产生的絮状物,最终得到纯净的人发角蛋白溶液,用Bradford蛋白浓度测定蛋白浓度,并储存于4℃冰箱中备用;4. Concentrate the human hair keratin solution. Pour the dialyzed human hair keratin solution into a round bottom flask, concentrate the solution with a rotary evaporator, and slowly heat up to a heating temperature of 55°C with a rotation speed of 5-20rpm. The concentrated human hair keratin solution was centrifuged again to remove the flocs produced in the vacuum concentration process, and finally a pure human hair keratin solution was obtained. The protein concentration was determined by Bradford protein concentration, and stored in a refrigerator at 4°C for use;
S2、复合水凝胶制备S2. Preparation of composite hydrogel
1、混悬液制备:称取0.08g壳聚糖粉末置于50ml离心管中,对人发角蛋白溶液进行稀释,把6ml稀释后的角蛋白溶液(20mg/ml)加入到离心管中,轻微摇晃使壳聚糖粉末与人发角蛋白溶液充分混合,并迅速用移液器向试管中加入人发角蛋白/壳聚糖共混液1%体积的乙酸使壳聚糖粉末质子化溶解,剧烈摇晃试管后得到人发角蛋白/壳聚糖混悬液,然后将姜黄素加入试管并摇晃均匀(1ml共混液中加入6mg姜黄素),将试管置于超声清洗仪中超声20min去除摇晃过程中产生的气泡,之后用注射器吸取混悬液加入到不同形状的模具中;1. Suspension preparation: Weigh 0.08g chitosan powder and place it in a 50ml centrifuge tube, dilute the human hair keratin solution, add 6ml diluted keratin solution (20mg/ml) into the centrifuge tube, Shake slightly to make the chitosan powder and human hair keratin solution fully mixed, and quickly add 1% acetic acid of human hair keratin/chitosan blend solution to the test tube with a pipette to protonate and dissolve the chitosan powder, Vigorously shake the test tube to obtain a human hair keratin/chitosan suspension, then add curcumin to the test tube and shake evenly (6mg curcumin is added to 1ml blend), put the test tube in an ultrasonic cleaner for 20min to remove the shaking process The bubbles generated in the medium, and then use the syringe to draw the suspension and add it to different shapes of molds;
2、混悬液冷冻干燥:把模具放于冰箱中,在-20℃下将混悬液迅速冷冻,冷冻后将模具转移至冷冻干燥机中冻干过夜;2. Freeze-drying of the suspension: put the mold in the refrigerator, freeze the suspension quickly at -20°C, and transfer the mold to a freeze dryer to freeze-dry overnight;
3、交联:配制3%三聚磷酸钠和pH=5的1.5M氯化钠溶液作为交联剂,加入交联剂浸没冻干的水凝胶静置交联20min,之后用蒸馏水反复清洗水凝胶去除多余的三聚磷酸钠和氯化钠,得到最终的复合水凝胶。3. Cross-linking: prepare 3% sodium tripolyphosphate and 1.5M sodium chloride solution with pH=5 as a cross-linking agent, add the cross-linking agent to immerse the freeze-dried hydrogel and let stand for cross-linking for 20 minutes, then wash it repeatedly with distilled water The hydrogel removes excess sodium tripolyphosphate and sodium chloride to obtain the final composite hydrogel.
上述实施例所用原料见如下表1。The raw materials used in the above examples are shown in Table 1 below.
表1Table 1
对比例1Comparative example 1
安装上述实施例1的制备方法,除了不加入姜黄素,其他步骤参照实施例2制出人发角蛋白/壳聚糖水凝胶。Install the preparation method of the above-mentioned
实验例Experimental example
姜黄素释放缓冲液配制:在烧杯中加入一定量的PBS,然后在旋转搅拌下缓慢加入0.5%的Tween-80,待Tween-80完全溶解后得到姜黄素释放缓冲液做空白对照,可将配制的姜黄素释放缓冲液在4℃保存备用。Preparation of curcumin release buffer: add a certain amount of PBS to the beaker, then slowly add 0.5% Tween-80 under rotating stirring, after Tween-80 is completely dissolved, the curcumin release buffer is obtained as a blank control, and the preparation The curcumin release buffer was stored at 4 °C for later use.
姜黄素标准品配制:称取10mg姜黄素,用姜黄素释放缓冲液溶解,转移到100mL容量瓶中定容,得到100μg/ml的姜黄素溶液;用姜黄素释放缓冲液将100μg/ml的姜黄素溶液稀释为浓度梯度为2μg/ml、3μg/ml、4μg/ml、5μg/ml、6μg/ml、10μg/ml的姜黄素标准溶液。在427nm处分别测定2μg/ml、3μg/ml、4μg/ml、5μg/ml、6μg/ml、10μg/ml的姜黄素标准溶液的吸光度并绘制浓度-吸光度的标准曲线。Curcumin standard preparation: Weigh 10mg curcumin, dissolve it with curcumin release buffer, transfer to a 100mL volumetric flask to obtain a 100 μg/ml curcumin solution; use curcumin release buffer to dissolve 100 μg/ml curcumin The curcumin solution was diluted to a curcumin standard solution with a concentration gradient of 2 μg/ml, 3 μg/ml, 4 μg/ml, 5 μg/ml, 6 μg/ml, and 10 μg/ml. Measure the absorbance of 2μg/ml, 3μg/ml, 4μg/ml, 5μg/ml, 6μg/ml, 10μg/ml curcumin standard solution at 427nm and draw the concentration-absorbance standard curve.
细胞划痕实验是分析细胞迁移能力的常用方法。它的原理是当细胞长到融合成单层状态时,在融合的单层细胞上人为制造一个空白区域,称为“划痕”。划痕边缘的细胞会逐渐迁移进入空白区域使“划痕”愈合,愈合速度快慢代表着细胞迁移能力的强弱。如图1,随着姜黄素浓度的增大,RSC96细胞划痕有着更快的愈合面积。与空白对照组比较,DMSO作为姜黄素的溶剂对RSC96划痕愈合面积没有影响。在姜黄素浓度大于等于0.1μg/mL时,姜黄素可以促进RSC96细胞划痕愈合。可见,姜黄素对于RSC96细胞迁移的促进需要达到一定浓度。Cell scratch assay is a common method to analyze cell migration ability. Its principle is to artificially create a blank area on the fused monolayer cells, called "scratch", when the cells grow to fuse into a monolayer state. Cells at the edge of the scratch will gradually migrate into the blank area to heal the "scratch", and the speed of healing represents the strength of cell migration. As shown in Figure 1, as the concentration of curcumin increased, the scratches of RSC96 cells had a faster healing area. Compared with the blank control group, DMSO as a solvent for curcumin had no effect on the healing area of RSC96 scratches. When the concentration of curcumin is greater than or equal to 0.1 μg/mL, curcumin can promote the scratch healing of RSC96 cells. It can be seen that curcumin needs to reach a certain concentration to promote the migration of RSC96 cells.
如图2的B,姜黄素释放缓冲液最大吸收波长是427nm,姜黄素溶液在427nm处的回归方程为y=0.1495x+0.012,R2=0.9996,由标准曲线可知,姜黄素浓度在2-10ug/mL范围内线性关系良好。As shown in B of Figure 2, the maximum absorption wavelength of the curcumin release buffer is 427nm, and the regression equation of the curcumin solution at 427nm is y=0.1495x+0.012, R 2 =0.9996, as can be seen from the standard curve, the curcumin concentration is between 2- The linear relationship is good in the range of 10ug/mL.
以PBS缓冲液模拟人体内液体环境,观察到负载姜黄素的人发角蛋白/壳聚糖水凝胶可以持续释放姜黄素达12天(图2的C)。与单纯的壳聚糖水凝胶相比,添加了人发蛋白的复合凝胶中的姜黄素释放更快。此外,随着人发角蛋白/壳聚糖水凝胶中人发角蛋白成分占比的增加,姜黄素的释放率增大。SEM显示随着人发角蛋白/壳聚糖水凝胶中人发角蛋白比例大的水凝胶有更大的孔密度,壳聚糖占比的减少则意味着更少的交联网络,水分子可以迅速扩散到水凝胶中,所以姜黄素有更快的释放。这种差异在在前6天较为显著,在6天后差异变小。这可能是因为随释放时间的推移水凝胶中姜黄素总量的减少,姜黄素对于RSC96细胞增殖和迁移的促进有浓度要求,而人发角蛋白/壳聚糖水凝胶的药物释放规律可以保证在局部神经损伤早期快速达到有效药物浓度,这可能有利于更好的促进神经损伤修复。Using PBS buffer to simulate the liquid environment in the human body, it was observed that the curcumin-loaded human hair keratin/chitosan hydrogel could continuously release curcumin for 12 days (Fig. 2C). Compared with pure chitosan hydrogel, curcumin was released faster in the composite gel with added human hair protein. In addition, with the increase of the proportion of human hair keratin in the human hair keratin/chitosan hydrogel, the release rate of curcumin increased. SEM showed that as the hydrogel with a large proportion of human hair keratin in the human hair keratin/chitosan hydrogel had a larger pore density, the decrease in the proportion of chitosan meant less cross-linking network, water The molecules can diffuse quickly into the hydrogel, so there is a faster release of curcumin. This difference is more significant in the first 6 days, and the difference becomes smaller after 6 days. This may be due to the reduction of the total amount of curcumin in the hydrogel with the release time, curcumin has a concentration requirement for the promotion of RSC96 cell proliferation and migration, and the drug release of human hair keratin/chitosan hydrogel can be Ensure that the effective drug concentration is quickly reached in the early stage of local nerve damage, which may be beneficial to better promote the repair of nerve damage.
动物实验Animal experiment
水凝胶制备:根据复合水凝胶的表征、细胞相容性和姜黄素的释放实验综合考虑,选取人发角蛋白壳聚糖为1:1的水凝胶进行动物实验。水凝胶和负载姜黄素的水凝胶制备步骤和之前实验相同,分别将人发角蛋白/壳聚糖共混液和人发角蛋白/壳聚糖/姜黄素混悬液以2ml/孔浇铸于6孔板,然后冻干、交联、洗涤、再冻干,灭菌后避光保存于4℃冰箱中。在动物实验时将水凝胶裁剪为0.8×0.5cm2大小,其中含姜黄素约500μg,手术时用无菌生理盐溶胀水平衡。Hydrogel preparation: According to the comprehensive consideration of the characterization of the composite hydrogel, the cytocompatibility and the release experiment of curcumin, the hydrogel with the human hair keratin chitosan ratio of 1:1 was selected for animal experiments. The preparation steps of hydrogel and curcumin-loaded hydrogel are the same as the previous experiments, and the human hair keratin/chitosan blend and the human hair keratin/chitosan/curcumin suspension are cast at 2ml/well Put it in a 6-well plate, then freeze-dry, cross-link, wash, freeze-dry again, and store in a refrigerator at 4°C in the dark after sterilization. During the animal experiment, the hydrogel was cut to a size of 0.8×0.5cm 2 , which contained about 500 μg of curcumin, and was balanced with sterile physiological saline swelling water during the operation.
动物分组:动物实验选用190-210g雄性SD大鼠。将16只SD大鼠随机分为4组每组4只,分别为假手术组(Sham)、单纯挤压伤对照组(Control)、人发角蛋白/壳聚糖水凝胶植入组(CK)和负载姜黄素复合水凝胶植入组(CKC)。Animal grouping: 190-210g male SD rats were selected for animal experiments. Sixteen SD rats were randomly divided into 4 groups with 4 rats in each group, namely the sham operation group (Sham), the simple crush injury control group (Control), and the human hair keratin/chitosan hydrogel implantation group (CK). ) and loaded curcumin composite hydrogel implant group (CKC).
手术步骤:术前一天大鼠禁食水,经过异氟烷吸入麻醉之后,将大鼠右后肢剃毛并用70%乙醇消毒,无菌条件下切开皮肤钝性分离各层组织,暴露右侧坐骨神经,在坐骨神经分叉上方的约5mm处,使用止血钳完全闭合坐骨神经30s。使用9-0尼龙线在距离损伤近端约1mm处标记,用4-0尼龙线缝合皮肤。Sham组大鼠暴露神经后不进行神经挤压,CK组和CKC组大鼠标记后在损伤神经周围包裹水凝胶。Surgical procedures: The rats were fasted for water one day before the operation. After isoflurane inhalation anesthesia, the right hind limbs of the rats were shaved and sterilized with 70% ethanol. Sciatic nerve, about 5mm above the bifurcation of the sciatic nerve, use a hemostat to completely close the sciatic nerve for 30 seconds. Use 9-0 nylon suture to mark approximately 1 mm from the proximal end of the injury, and suture the skin with 4-0 nylon suture. The rats in the Sham group were not subjected to nerve extrusion after the nerve was exposed, and the rats in the CK group and CKC group were marked and wrapped with hydrogel around the injured nerve.
将相同的人发角蛋白水凝胶植入额外的4只大鼠神经周围以研究水凝胶的降解情况。所有大鼠在手术后均在相同环境中饲养,定期观察和记录大鼠的生存状态和体重变化,在规定时间麻醉取材。The same human hair keratin hydrogel was implanted around nerves in four additional rats to study hydrogel degradation. All rats were reared in the same environment after the operation, the living status and body weight changes of the rats were regularly observed and recorded, and samples were collected under anesthesia at the specified time.
术后第7、14、21、28天,测量所有实验大鼠坐骨神经指数。大鼠双后足均匀涂抹墨水后,将大鼠放于80×10×10cm长方形盒子的一端,让其自行向另一端行走,盒子底部铺有平整的白纸,每侧后肢会各留下5-6个足印。实验前,已对大鼠进行反复的训练,以保证大鼠迅速通过盒子而不停留。测量大鼠足印数据并计算坐骨神经指数。选择印迹清晰的足印分别测量正常足(N)和伤侧足(E)的3个指标:A、PL(足印长度);B、TS(足趾宽度);C、IT(中间足趾宽度)。将上述数据代入坐骨神经指数(Sciatic Function Index)公式,计算并记录坐骨神经功能指数。坐骨神经功能指数SFI=0为正常,-100为完全损伤。On the 7th, 14th, 21st and 28th day after operation, the sciatic nerve indexes of all experimental rats were measured. After smearing ink evenly on both hind feet of the rat, put the rat on one end of a rectangular box of 80×10×10 cm, and let it walk to the other end by itself. The bottom of the box is covered with flat white paper, and 5 -6 footprints. Before the experiment, the rats have been trained repeatedly to ensure that the rats pass through the box quickly without staying. Rat footprint data were measured and the sciatic nerve index was calculated. Select clear footprints to measure three indexes of normal foot (N) and injured foot (E): A, PL (footprint length); B, TS (toe width); C, IT (middle toe width) width). Substitute the above data into the sciatic nerve index (Sciatic Function Index) formula, calculate and record the sciatic nerve function index. Sciatic nerve function index SFI=0 is normal, and -100 is complete damage.
SFI=109.5(ETS-NTS)/NTS-38.3(EPL-NPL)/NPL+13.3(EIT-NIT)/NIT-8.8。SFI=109.5(ETS-NTS)/NTS-38.3(EPL-NPL)/NPL+13.3(EIT-NIT)/NIT-8.8.
术后第28天,对实验大鼠进行神经电生理检测。用0.4ml/100g水合氯醛将大鼠完全麻醉后,如前所述对大鼠右边后肢备皮、消毒、显露损伤节段神经。将记录电极插入腓肠肌腹部记录信号,刺激电极分别在损伤神经的近端和远端进行刺激,并记录两次刺激点的距离。通过电脑记录复合肌肉动作电位(compound muscle action potential,CMAP)和振幅的潜伏期(latency),计算神经传导速度(nerve conduction velocity,NCV)。On the 28th day after operation, neurophysiological detection was performed on the experimental rats. After the rats were fully anesthetized with 0.4ml/100g chloral hydrate, the right hind limbs of the rats were skinned, disinfected, and the injured segmental nerves were exposed as described above. The recording electrodes were inserted into the abdomen of the gastrocnemius muscle to record signals, the stimulating electrodes were respectively stimulated at the proximal end and the distal end of the injured nerve, and the distance between the two stimulation points was recorded. The compound muscle action potential (CMAP) and amplitude latency (latency) were recorded by computer, and the nerve conduction velocity (NCV) was calculated.
神经传导速度=刺激点间的距离/(刺激点潜伏期差值)。Nerve conduction velocity = distance between stimulation points/(difference in latency between stimulation points).
神经电生理检测后,根据标记点切取损伤侧坐骨神经远端并用2.5%戊二醛固定24小时。在1%四氧化锇中再固定1小时后用乙醇梯度脱水并用环氧树脂包埋神经。然后使用超薄切片机将神经切为厚度1μm的切片。将切片浸渍于0.5%的甲苯胺蓝染色30min,再用醋酸分色并用清水清洗3次。切片经封片剂封片后在光学显微镜下观察拍照记录神经的髓鞘结构。并使用ImageJ软件对神经轴突计数。After the nerve electrophysiological examination, the distal end of the sciatic nerve on the injured side was cut according to the marked points and fixed with 2.5% glutaraldehyde for 24 hours. After an additional 1 h of fixation in 1% osmium tetroxide, dehydrate with an ethanol gradient and embed the nerves with epoxy resin. The nerves were then sliced into 1 μm thick slices using an ultramicrotome. The sections were dipped in 0.5% toluidine blue and stained for 30 min, then separated with acetic acid and washed three times with water. After the slices were sealed with a mounting medium, the myelin sheath structure of the nerves was observed and photographed under an optical microscope. And use ImageJ software to count the axons.
神经组织取材与固定过程与甲苯胺蓝染色过程相同。四氧化锇固定后的神经组织用预先冷却PBS冲洗3次每次15min,再用乙醇梯度脱水并在环氧树脂中包埋。包埋后的组织进行70nm组织超薄切片,分别用醋酸铀染色30min和柠檬酸铅染色10min。染色完成后于透射电镜下观察记录神经组织横断面照片。使用ImageJ软件对神经轴突的内径、外径和髓鞘厚度。The process of collecting and fixing nerve tissue was the same as that of toluidine blue staining. Nerve tissues fixed with osmium tetroxide were rinsed three times with pre-cooled PBS for 15 min each, then dehydrated with gradient ethanol and embedded in epoxy resin. The embedded tissue was ultra-thin sectioned at 70 nm, stained with uranyl acetate for 30 min and lead citrate for 10 min, respectively. After the staining was completed, the cross-sectional photos of the nerve tissue were observed and recorded under a transmission electron microscope. The inner diameter, outer diameter and myelin sheath thickness of nerve axons were analyzed using ImageJ software.
为评估人发角蛋白壳/聚糖水凝胶神经组织中的生物相容性,我们检测了各组实验大鼠4周内血液中两种炎症因子(TNF-α,IL-10)的表达水平,测定大鼠体重变化,并对各组大鼠重要器官进行了HE染色以观察器官主要结构变化。此外,我们还将水凝胶植入健康大鼠神经组织周围以评估水凝胶生物降解性。In order to evaluate the biocompatibility of human hair keratin shell/glycan hydrogel in nerve tissue, we detected the expression levels of two inflammatory factors (TNF-α, IL-10) in the blood of experimental rats in each group within 4 weeks , measured the body weight changes of the rats, and carried out HE staining on the important organs of the rats in each group to observe the main structural changes of the organs. In addition, we also implanted the hydrogel around the nerve tissue of healthy rats to evaluate the hydrogel biodegradability.
神经电生理检测后,分离大鼠双侧腓肠肌,称重后用4%多聚甲醛固定24小时。固定过的腓肠肌经过乙醇梯度脱水、石蜡包埋、切片后,分别用Ehrlich苏木精染液、丽春红-酸性复红液和醋酸苯胺蓝染液各染色5min,然后经乙醇梯度脱水、封片并室温晾干。在光学显微镜下观察记录腓肠肌纤维的形态变化,并用ImageJ软件测量腓肠肌纤维横截面积。After neurophysiological testing, the bilateral gastrocnemius muscles of rats were isolated, weighed and fixed with 4% paraformaldehyde for 24 hours. The fixed gastrocnemius muscle was dehydrated by ethanol gradient, embedded in paraffin, and sectioned, and then stained with Ehrlich hematoxylin staining solution, Ponceau red-acid fuchsin solution and aniline blue acetate staining solution for 5 min respectively, and then dehydrated by ethanol gradient and sealed. slice and dry at room temperature. The morphological changes of gastrocnemius muscle fibers were observed and recorded under an optical microscope, and the cross-sectional area of gastrocnemius muscle fibers was measured with ImageJ software.
在手术后第0、1、、3、7、14、28天,通过内眦取血法采集不同实验组大鼠的血液,每次约0.8ml,用促凝管收集样本,样品室温放置30分钟。然后离心(1000rpm,15min),吸取上层血清保存于﹣80℃冰箱中备用。使用ELISA试剂盒测定大鼠血清中的炎症细胞因子:IL-10、TNF-α。检测过程依照试剂盒说明书进行,简而言之,用酶标仪检测450nm处各个样本的吸光度。通过不同浓度的细胞因子标准物做出标准曲线(浓度-吸光度),用标准曲线计算样品细胞因子的浓度。On the 0th, 1st, 3rd, 7th, 14th, and 28th days after the operation, the blood of rats in different experimental groups was collected by the inner canthus blood collection method, about 0.8ml each time, and the samples were collected with coagulation-promoting tubes, and the samples were placed at room temperature for 30 minute. Then centrifuge (1000rpm, 15min), absorb the upper serum and store it in a -80°C refrigerator for later use. The inflammatory cytokines in rat serum: IL-10 and TNF-α were determined by ELISA kit. The detection process was carried out according to the instructions of the kit. In short, the absorbance of each sample at 450 nm was detected with a microplate reader. A standard curve (concentration-absorbance) was made through cytokine standards of different concentrations, and the concentration of the cytokine in the sample was calculated using the standard curve.
第28天,大鼠在神经和肌肉取材后被安乐死,分别取其心、肝、脾、肺、肾脏器,用4%多聚甲醛中固定24小时。固定过的组织经过乙醇梯度脱水、石蜡包埋、切片,然后用二甲苯脱去切片中的石蜡,用乙醇(从高浓度到低浓度)水化,再用苏木精和伊红染料染色,染色时间为2-3min。染色后用中性树胶封片,室温自然风干,并在光学显微镜下观察器官主要结构变化并拍照记录。On the 28th day, the rats were euthanized after the nerve and muscle samples were taken, and the heart, liver, spleen, lung, and kidney organs were removed respectively, and fixed in 4% paraformaldehyde for 24 hours. The fixed tissue was dehydrated by ethanol gradient, embedded in paraffin, sectioned, then deparaffinized in the section with xylene, hydrated with ethanol (from high concentration to low concentration), and then stained with hematoxylin and eosin dyes. Dyeing time is 2-3min. After staining, the slides were sealed with neutral gum, air-dried at room temperature, and the main structural changes of the organs were observed under an optical microscope and recorded by taking pictures.
使用ImajeJ软件进行图像处理,使用Graphpad prism7.0和Origin2021进行数据处理和分析。所有数据均表示为平均值±平均值的标准误差。通过单因素方差分析(ANOVA)比较组间的差异。P值<0.05被认为具有统计学意义。ImajeJ software was used for image processing, and Graphpad prism7.0 and Origin2021 were used for data processing and analysis. All data are expressed as mean ± standard error of the mean. Differences between groups were compared by one-way analysis of variance (ANOVA). A P value <0.05 was considered statistically significant.
为评估人发角蛋白壳聚糖水凝胶神经组织中的生物相容性,我们检测了各组实验大鼠4周内血液中两种炎症因子(TNF-α,IL-10)的表达水平,测定大鼠体重变化,并对各组大鼠重要器官进行了HE染色以观察器官主要结构变化。此外,我们还将水凝胶植入健康大鼠神经组织周围以评估水凝胶生物降解性。In order to evaluate the biocompatibility of human hair keratin chitosan hydrogel in nerve tissue, we detected the expression levels of two inflammatory factors (TNF-α, IL-10) in the blood of experimental rats in each group within 4 weeks, The weight changes of the rats were measured, and HE staining was performed on the vital organs of the rats in each group to observe the main structural changes of the organs. In addition, we also implanted the hydrogel around the nerve tissue of healthy rats to evaluate the hydrogel biodegradability.
实验结果表明,水凝胶可在8周内降解(图3的A)。所有实验的大鼠均未出现死亡,手术后大鼠均可正常进食,术后第1-3天体重无明显增加这可能与手术应激相关,之后体重呈正常增长趋势,同一时间的各组大鼠体重无明显差异(图3的C)。对于机体而言,外源性异物植入后会产生一系列宿主反应,主要包括局部反应、全身毒性反应、急性炎症、慢性炎症反应和异物反应等。炎症发生时,机体的许多细胞因子会过表达以激活炎症通路,所以血液中炎症相关的细胞因子表达水平可以反应机体的炎症程度,这些炎症因子包括:TNF-α、IL-6、IL-8和IL-10等。实验结果表明,各组大鼠的TNF-α,IL-10表达水平无显著差异(图3的D和3的E)。水凝胶的植入不会引起强烈的炎症反应。HE染色结果表明,与假手术组大鼠比较,CK组和CKC组无明显差异,所有组织器官细胞形态良好,无炎症细胞聚集,心肌排列规则,可见正常的肝小叶、脾脏的白髓和红髓、肺泡、肾小球等组织,无明显病理性组织。以上结果说明人发角蛋白壳聚糖水凝胶具备良好的生物相容性和可降解性。The experimental results showed that the hydrogel could be degraded within 8 weeks (Fig. 3A). All the rats in the experiments did not die, and the rats could eat normally after the operation, and there was no significant increase in body weight on the first 1-3 days after the operation, which may be related to the stress of the operation, after which the body weight showed a normal growth trend. There was no significant difference in body weight of the rats (Figure 3C). As far as the body is concerned, a series of host reactions will occur after the implantation of exogenous foreign bodies, mainly including local reactions, systemic toxic reactions, acute inflammation, chronic inflammatory reactions, and foreign body reactions. When inflammation occurs, many cytokines in the body will be overexpressed to activate inflammatory pathways, so the expression level of inflammation-related cytokines in the blood can reflect the degree of inflammation in the body. These inflammatory factors include: TNF-α, IL-6, IL-8 and IL-10 etc. The experimental results showed that there was no significant difference in the expression levels of TNF-α and IL-10 among the rats in each group (D in FIG. 3 and E in FIG. 3 ). The implantation of the hydrogel did not cause a strong inflammatory response. The results of HE staining showed that compared with the rats in the sham operation group, there was no significant difference between the CK group and the CKC group. All tissues and organs had good cell morphology, no inflammatory cell aggregation, regular arrangement of the myocardium, normal liver lobule, white pulp of the spleen and red Marrow, alveoli, glomerulus and other tissues, without obvious pathological tissue. The above results show that the human hair keratin chitosan hydrogel has good biocompatibility and degradability.
坐骨神经支配着后肢运动,其损伤后大鼠后足蜷缩,行走时五趾伸展障碍同时出现拖足现象。SFI通过对足印的综合分析,量化了后足功能恢复,SFI=0为正常,-100为完全损伤。术后所有挤压损伤大鼠均出现拖足现象,说明神经损伤后大鼠后足运动功能出现障碍。如图4,在术后第2周,与对照组相比,CKC组大鼠SFI明显升高(P<0.05),而CK组无显著差异(P>0.05),这可能与损伤早期复合水凝胶中姜黄素的释放有关,损伤局部的姜黄素促进了神经修复。在第3、4周,与对照组相比,CKC组和CK组大鼠SFI均明显升高(P<0.05),说明复合水凝胶本身也具备促进神经修复的功能。复合水凝胶对神经损伤修复的促进作用可能由于姜黄素的负载而增强。The sciatic nerve innervates the movement of the hind limbs. After the injury, the hind feet of the rats curled up, and the stretching of the five toes was impaired while the feet dragged when walking. SFI quantifies hindfoot functional recovery by comprehensive analysis of footprints, with SFI = 0 as normal and -100 as complete injury. All crush-injured rats showed foot dragging after operation, which indicated that the motor function of the rear feet of the rats was impaired after nerve injury. As shown in Figure 4, at the 2nd week after surgery, compared with the control group, the SFI of rats in the CKC group was significantly increased (P<0.05), while there was no significant difference in the CK group (P>0.05), which may be related to the combination of water in the early stage of injury. The curcumin in the gel is related to the release of curcumin, and curcumin in the damaged part promotes nerve repair. At the 3rd and 4th week, compared with the control group, the SFI of the rats in the CKC group and the CK group was significantly increased (P<0.05), indicating that the composite hydrogel itself also has the function of promoting nerve repair. The promotion effect of the composite hydrogel on nerve injury repair may be enhanced due to the loading of curcumin.
周围神经挤压损伤后发生特征性的病理变化,即Wallerian变性,这会使损远端的髓鞘崩解轴突变性,神经传导也因此丧失;而新的轴突会由近端向远端生长,重新支配靶器官,神经传导功能也逐渐恢复。这种损伤和恢复过程可通过复合肌肉动作电位(CMAP)检测。如图5,在术后第4周,与对照组相比,CK组和CKC组的CMAP峰值振幅更大(P<0.01);而CKC组的CMAP峰值振幅也大于CK组(P<0.05)。同样,CK组和CKC组的再生神经传导速度也更快(P<0.01);CKC组的神经传导速度大于CK组(P<0.01)。实验结果表明复合水凝胶和负载了姜黄素水凝胶都可以促进损伤神经传导功能的恢复,而负载了姜黄素的水凝胶要优于单纯的水凝胶。这可能与水凝胶中姜黄素局部的释放有关,损伤局部的姜黄素促进了神经修复。The characteristic pathological changes after peripheral nerve crush injury, that is, Wallerian degeneration, will cause the myelin sheath disintegration axon degeneration at the distal end of the damage, and the nerve conduction will also be lost; while the new axon will be from the proximal end to the distal end Growth, reinnervation of target organs, and gradual restoration of nerve conduction function. This injury and recovery process can be detected by the compound muscle action potential (CMAP). As shown in Figure 5, at the 4th week after surgery, compared with the control group, the peak amplitude of CMAP in the CK and CKC groups was greater (P<0.01); and the peak amplitude of CMAP in the CKC group was also greater than that in the CK group (P<0.05) . Similarly, the regenerated nerve conduction velocity was faster in the CK and CKC groups (P<0.01); the nerve conduction velocity in the CKC group was greater than that in the CK group (P<0.01). The experimental results show that both the composite hydrogel and the curcumin-loaded hydrogel can promote the recovery of damaged nerve conduction function, and the curcumin-loaded hydrogel is better than the simple hydrogel. This may be related to the local release of curcumin in the hydrogel, and curcumin at the damaged site promotes nerve repair.
为了研究神经再生组织学的恢复,我们对损伤神经远端进行横切,通过甲苯胺蓝染色观察轴突数量变化,通过透射电子显微镜观察神经轴突直径和髓鞘厚度变化。如图6的A(甲苯胺蓝染色的神经),与假手术组相比,损伤后的神经纤维表现为有髓神经纤维分布不均、大小不一、轴突形状不规则;但与对照组相比CK组和CKC组神经纤维这些表现有所改善。轴突数量统计分析表明(图6的C),CK组和CKC组显著多于对照组(P<0.01;P<0.01),而CKC多于CK组(P<0.01);如图6的B,通过透射电镜观察,对照组神经轴突内直径和髓鞘厚度明显减小,而CK组和CKC组种种改变显著改善。轴突内直径统计分析表明(图6的D),CK组和CKC组显著大于对照组(P<0.05;P<0.01)。轴突内直径/总纤维直径(G-ratio)统计分析表明(图6的E),CK组和CKC组显著小于对照组(P<0.05;P<0.01),CKC小于CK组(P<0.05),更接近假手术组的G-ratio。髓鞘厚度统计分析表明(图6的F),CK组和CKC组显著大于对照组(P<0.05;P<0.01),CKC组大于CK组(P<0.01)。实验结果表明复合水凝胶和负载姜黄素的复合水凝胶都可以促进大鼠神经挤压伤后神经恢复,而负载姜黄素的水凝胶促进效果优于单纯的复合水凝胶,其中显著增加了损伤神经的髓鞘厚度。In order to study the histological recovery of nerve regeneration, we cross-sectioned the distal end of the injured nerve, observed the changes in the number of axons by staining with toluidine blue, and observed the changes in the diameter of axons and the thickness of myelin sheath by transmission electron microscopy. As shown in Figure 6 A (toluidine blue-stained nerve), compared with the sham operation group, the damaged nerve fibers showed uneven distribution of myelinated nerve fibers, different sizes, and irregular shape of axons; but compared with the control group These performances were improved in nerve fibers compared to CK and CKC groups. Statistical analysis of the number of axons showed (C in Figure 6), the CK group and CKC group were significantly more than the control group (P<0.01; P<0.01), and the CKC group was more than the CK group (P<0.01); as in Figure 6B , observed by transmission electron microscope, the inner diameter of axons and the thickness of myelin in the control group were significantly reduced, while the changes in the CK group and CKC group were significantly improved. Statistical analysis of the inner diameter of the axons showed (D in Figure 6) that the CK group and CKC group were significantly larger than the control group (P<0.05; P<0.01). The statistical analysis of axon inner diameter/total fiber diameter (G-ratio) showed (Figure 6E), the CK group and CKC group were significantly smaller than the control group (P<0.05; P<0.01), and the CKC group was smaller than the CK group (P<0.05 ), which is closer to the G-ratio of the sham group. Statistical analysis of myelin sheath thickness showed (Figure 6F), the CK group and CKC group were significantly larger than the control group (P<0.05; P<0.01), and the CKC group was larger than the CK group (P<0.01). The experimental results show that both the composite hydrogel and the composite hydrogel loaded with curcumin can promote nerve recovery after nerve crush injury in rats, and the hydrogel loaded with curcumin has a better promoting effect than that of the simple composite hydrogel, among which significantly Increased myelin sheath thickness of injured nerves.
腓肠肌是坐骨神经的靶器官,神经损伤后失去神经支配的腓肠肌会出现萎缩,表现为肌肉纤维变小、胶原蛋白增加和肌肉重量减轻。我们测试了腓肠肌重量、肌纤维横截面积,以评估腓肠肌的萎缩情况。如图7的A,通过腓肠肌外观可以看出神经损伤侧腓肠肌出现明显萎缩,而CK组和CKC组萎缩较轻。腓肠肌相对湿重统计分析表明,CKC组显著大于对照组(P<0.05)而CK组与对照组无明显差异。通过腓肠肌横截面的Masson染色可以看出神经损伤后腓肠肌肌纤维明显缩小而肌纤维间隙明显增大,而CK组和CKC组则有所改善(图7的B)。肌纤维面积占比统计分析表明,CK组和CKC组显著大于对照组(P<0.01;P<0.01),CKC组显著大于CK组。实验结果表明,水凝胶和负载姜黄素的水凝胶减轻了神经损伤后腓肠肌的萎缩,这是由于水凝胶和负载姜黄素的水凝胶促进了损伤后的神经再生,缩短了腓肠肌视神经支配时间,进而减轻了肌肉的萎缩。负载姜黄素的水凝胶比单纯的水凝胶表现出更好的效果。The gastrocnemius muscle is the target organ of the sciatic nerve, and the gastrocnemius muscle that loses its innervation after nerve injury will atrophy, manifested by smaller muscle fibers, increased collagen, and reduced muscle weight. We tested the gastrocnemius muscle weight, muscle fiber cross-sectional area to evaluate the atrophy of the gastrocnemius muscle. As shown in Figure 7A, the appearance of the gastrocnemius muscle showed obvious atrophy on the side of the nerve injury, while the atrophy was milder in the CK group and CKC group. Statistical analysis of the relative wet weight of gastrocnemius muscle showed that the CKC group was significantly larger than the control group (P<0.05), but there was no significant difference between the CK group and the control group. Through Masson staining of the gastrocnemius cross section, it can be seen that the gastrocnemius muscle fibers were significantly reduced and the muscle fiber gap was significantly increased after nerve injury, while the CK group and CKC group were improved (Figure 7B). Statistical analysis of muscle fiber area ratio showed that the CK group and CKC group were significantly larger than the control group (P<0.01; P<0.01), and the CKC group was significantly larger than the CK group. The experimental results showed that the hydrogel and curcumin-loaded hydrogel alleviated the atrophy of the gastrocnemius muscle after nerve injury, which was due to the fact that the hydrogel and the curcumin-loaded hydrogel promoted nerve regeneration after injury and shortened the gastrocnemius optic nerve Control time, thereby reducing muscle atrophy. Curcumin-loaded hydrogels showed better results than pure hydrogels.
对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。It will be apparent to those skilled in the art that the invention is not limited to the details of the above-described exemplary embodiments, but that the invention can be embodied in other specific forms without departing from the spirit or essential characteristics of the invention. Accordingly, the embodiments should be regarded in all points of view as exemplary and not restrictive, the scope of the invention being defined by the appended claims rather than the foregoing description, and it is therefore intended that the scope of the invention be defined by the appended claims rather than by the foregoing description. All changes within the meaning and range of equivalents of the elements are embraced in the present invention.
此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。In addition, it should be understood that although this specification is described according to implementation modes, not each implementation mode only includes an independent technical solution, and this description in the specification is only for clarity, and those skilled in the art should take the specification as a whole , the technical solutions in the various embodiments can also be properly combined to form other implementations that can be understood by those skilled in the art.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210340766.9A CN114573839B (en) | 2022-03-23 | 2022-03-23 | A preparation method of human hair keratin/chitosan hydrogel loaded with curcumin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210340766.9A CN114573839B (en) | 2022-03-23 | 2022-03-23 | A preparation method of human hair keratin/chitosan hydrogel loaded with curcumin |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114573839A CN114573839A (en) | 2022-06-03 |
CN114573839B true CN114573839B (en) | 2023-07-11 |
Family
ID=81785745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210340766.9A Active CN114573839B (en) | 2022-03-23 | 2022-03-23 | A preparation method of human hair keratin/chitosan hydrogel loaded with curcumin |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114573839B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116763724B (en) * | 2023-07-20 | 2023-11-21 | 江苏创健医疗科技股份有限公司 | Preparation method of recombinant collagen hydrogel loaded with curcumin and application of recombinant collagen hydrogel in uterine cavity adhesion treatment |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104922734B (en) * | 2015-05-21 | 2017-11-24 | 东南大学 | Promote injectable chitosan composite aquogel of myocardial repair and preparation method thereof |
CN110408187B (en) * | 2019-08-01 | 2023-10-13 | 山东大学 | Injectable chitosan-based hydrogel with self-healing properties and high mechanical strength and its preparation method and application |
-
2022
- 2022-03-23 CN CN202210340766.9A patent/CN114573839B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN114573839A (en) | 2022-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102516009B1 (en) | Amniotic membrane powder and its use in wound healing and tissue engineering constructs | |
US9139664B2 (en) | Hemostatic compositions and therapeutic regimens | |
CN107519534B (en) | Fabrication method of polyethylene glycol modified graphene oxide-loaded quercetin cross-linked acellular dermal matrix 3D drug composite scaffold | |
CN106039416A (en) | Chitosan-sericin composite biological scaffold as well as preparation method and application thereof | |
PT101140A (en) | PROCESS FOR THE PURIFICATION OF POLYSACARIDES AND ULTRA-PURSUIT POLYSTACARIDE MATERIALS FOR MEDICAL USE SO OBTAINED | |
JP2017531533A (en) | Biomaterial scaffold material for regenerating oral mucosa | |
US20210393396A1 (en) | Dermal layer for grafting having improved graft survival rate and method for producing same | |
US20190060348A1 (en) | Treatment of disease with poly-n-acetylglucosamine nanofibers | |
CN113940949A (en) | A kind of GelMA hydrogel microneedle loaded with exosomes and its preparation method and application | |
CN115501253A (en) | Preparation of combined stem cell and hydrogel biomaterial and application of combined stem cell and hydrogel biomaterial in spinal cord injury | |
KR101916759B1 (en) | The Method of High-yield and High-purity Manufacturing of Allo-collagen Composition Extracted From Human origin | |
CN114573839B (en) | A preparation method of human hair keratin/chitosan hydrogel loaded with curcumin | |
Sun et al. | Curcumin-loaded keratin-chitosan hydrogels for enhanced peripheral nerve regeneration | |
RU2706726C1 (en) | Wound coating | |
Li et al. | Highly adhesive self-reinforce hydrogel for the amelioration of intervertebral disc degeneration: Eliminating reactive oxygen species and regulating extracellular matrix | |
WO2015164733A1 (en) | Compositions comprising cyclodextrin incorporated collagen matrices for use in biomedical applications | |
CN106075575A (en) | A kind of composite for knee osteoarthritis repair of cartilage and preparation method thereof | |
KR101095940B1 (en) | Injectable Insoluble Globin Implant | |
Lee et al. | Subcutaneous toxicity of a dual ionically cross-linked atelocollagen and sodium hyaluronate gel: Rat in vivo study for biological safety evaluation of the injectable hydrogel | |
CN110624112A (en) | Hydrogel connected with prostaglandin E2, and preparation method and application thereof | |
CN116440059A (en) | Cell-free fat extract loaded soluble microneedle and preparation method and application thereof | |
Lv et al. | Crocin-1 laden thermosensitive chitosan-based hydrogel with smart anti-inflammatory performance for severe full-thickness burn wound therapeutics | |
CN112353997A (en) | Preparation method and application of absorbable collagen sponge | |
CN111956784A (en) | Pharmaceutical preparation, method for the production thereof and use thereof | |
CN118542973B (en) | A method for preparing a pilose antler blood peptide preparation for promoting bone growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231207 Address after: 130000 No. 2699 Qianjin Street, Jilin, Changchun Patentee after: Jilin University Patentee after: CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY CHINESE ACADEMY OF SCIENCES Address before: 130000 No. 2699 Qianjin Street, Jilin, Changchun Patentee before: Jilin University |
|
TR01 | Transfer of patent right |